Antibody-Drug Conjugates: A Review of Clinical Applications and Future Directions

• ADCs combine antibody specificity with cytotoxic payloads, improving therapeutic index. • Recent FDA approvals have expanded ADC use in both solid and hematologic cancers. • Novel linker and payload technologies are enhancing stability and reducing off-target toxicity. • Future ADCs will incorporate bispecific formats and immunomodulatory mechanisms.